Afatinib and Nivolumab as Treatment of Platinum- and Cetuximab-Refractory Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2018
At a glance
- Drugs Afatinib (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 19 Dec 2018 Planned End Date changed from 1 Oct 2022 to 1 Nov 2022.
- 19 Dec 2018 Planned Primary Completion Date changed from 1 Oct 2021 to 1 Nov 2021.
- 19 Dec 2018 Status changed from not yet recruiting to recruiting.